Bonekamp David, Wolf Maya B, Edler Christopher, Katayama Sonja, Schlemmer Heinz-Peter, Herfarth Klaus, Röthke Matthias
Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Radiother Oncol. 2016 Aug;120(2):313-9. doi: 10.1016/j.radonc.2016.05.012. Epub 2016 May 26.
To characterize parametric changes measured by sequential dynamic contrast enhanced perfusion MRI (DCE-MRI) during primary proton and carbon ion irradiation of prostate cancer using a novel hypofractionated raster scan technique to determine the potential of pharmacokinetic analysis for monitoring treatment effects of this novel irradiation scheme.
Ninety-two patients were evaluated prospectively with DCE-MRI at baseline, day 10 during therapy, and 6weeks, 6months and 18months after treatment completion. After motion correction and co-registration to morphological T2-weighted images, tumors and normal appearing contralateral parenchyma (NACP) were segmented manually on T2W images and ROI statistics calculated for pharmacokinetic parameters K(trans), kep and ve using the standard Tofts model.
The volume transfer constant (K(trans), p<0.001/p=0.010) and the leakage space partial volume (ve, p<0.001/p=0.005) showed a statistically significant increase during therapy with protons and carbon ions, respectively. Parametric increases occurred only in patients naive to antihormonal therapy (AHT), and were maximal 10days after the begining of treatment. The rate constant (kep) showed a significant increase only for proton, but not for carbon irradiation (p=0.021). Statistically significant differences between PC and NACP were observed for all parameters (p<0.001). AHT naïve patients with persistent PSA elevation above 1ng/ml at 12months experienced statistically significant elevation of K(trans) and ve compared to those with PSA suppression (p=0.04/p=0.023).
DCE parametric changes following ion particle irradiation of the prostate have not been previously reported. Their development into potential non-invasive imaging biomarkers for assessment of treatment response and efficacy is expected to be aided by the data on the magnitude and temporal evolution of parametric responses of cancer and normal tissue during and after therapy presented here, especially the changes of K(trans) and ve during therapy and their different measurement levels within tumors and in normal appearing contralateral tissue.
使用一种新型的大分割光栅扫描技术,对前列腺癌质子和碳离子初次照射期间通过序贯动态对比增强灌注磁共振成像(DCE-MRI)测量的参数变化进行表征,以确定药代动力学分析监测这种新型照射方案治疗效果的潜力。
前瞻性评估92例患者,在基线、治疗第10天、治疗完成后6周、6个月和18个月进行DCE-MRI检查。在运动校正并与形态学T2加权图像配准后,在T2W图像上手动分割肿瘤和对侧正常实质(NACP),并使用标准Tofts模型计算药代动力学参数K(trans)、kep和ve的ROI统计数据。
容积转运常数(K(trans),p<0.001/p=0.010)和渗漏空间部分容积(ve,p<0.001/p=0.005)分别在质子和碳离子治疗期间显示出统计学上的显著增加。参数增加仅发生在未接受抗激素治疗(AHT)的患者中,且在治疗开始后10天达到最大值。速率常数(kep)仅在质子照射时显示出显著增加,而碳离子照射时未显示(p=0.021)。所有参数在前列腺癌(PC)和NACP之间均观察到统计学上的显著差异(p<0.001)。与PSA抑制的患者相比,12个月时PSA持续升高超过1ng/ml的未接受AHT患者的K(trans)和ve有统计学上的显著升高(p=0.04/p=0.023)。
此前尚未报道前列腺离子粒子照射后的DCE参数变化。本文提供的关于治疗期间和治疗后癌症及正常组织参数反应的幅度和时间演变的数据,尤其是治疗期间K(trans)和ve的变化以及它们在肿瘤和对侧正常组织中的不同测量水平,有望有助于将其发展为评估治疗反应和疗效的潜在非侵入性成像生物标志物。